Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
21.05 USD | -1.27% | -12.98% | -30.73% |
Mar. 25 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
Mar. 22 | Intellia Therapeutics Ends Development Agreement With Regeneron Pharmaceuticals | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-30.73% | 2.06B | |
-2.06% | 41.35B | |
+42.15% | 40.38B | |
+1.45% | 39.05B | |
-14.19% | 26.67B | |
+2.03% | 24.07B | |
-24.87% | 18.36B | |
-3.71% | 11.68B | |
+20.82% | 11.6B | |
+7.45% | 11.15B |
- Stock Market
- Equities
- NTLA Stock
- News Intellia Therapeutics, Inc.
- Guggenheim Adjusts Price Target for Intellia Therapeutics to $120 From $150, Maintains Buy Rating